Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Specific Use-results Study of IMFINZI Intravenous Infusion 120 mg,500mg in Patients With Curatively Unresectable Biliary Tract Cancer

NCT05835778 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05835778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05835778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Specific Use-results Study of IMFINZI Intravenous Infusion 120 mg,500mg in Patients With Curatively Unresectable Biliary Tract Cancer
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
June 6, 2023
Completion date
November 21, 2025
Enrollment
236 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer